ALSO READUnichem Laboratories standalone net profit declines 11.28% in the September 2016 quarter Board of Unichem Laboratories to consider Q3 and 9M results Unichem Labs gets USFDA nod for arthritis drug Unichem Labs gets USFDA nod for migraine tablets Unichem Labs Q2 net slips 11 pc at Rs 20.52 cr
From USFDAUnichem Laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg & 20mg, which are therapeutically equivalent to Feldene Capsules 10mg & 20mg of Pfizer, Inc. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA). For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg given orally once daily. If desired, the daily dose may be divided. Usually lowest effective dosage for the shortest duration, consistent with individual patient treatment goals is recommended. The product will be commercialized from Unichem's Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)